Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 2/2014

01-02-2014 | Research Article

Association between Cyclin D1 polymorphism and oral cancer susceptibility: a meta-analysis

Authors: Lili Wang, Zhiying Wang, Xiuqiu Gao, Xin Li, Xirao Sun, Changfu Liu

Published in: Tumor Biology | Issue 2/2014

Login to get access

Abstract

Data from several case–control studies on the relation between the Cyclin D1 (CCND1) G870A polymorphism and oral cancer susceptibility implicated conflicting conclusions. Thus, a meta-analysis was performed to derive a more precise evaluation of the association. We searched PubMed and Embase for related studies that had been published in English and eight available studies were finally included in the meta-analysis. Odd ratios (ORs) and 95 % confidence intervals (CIs) were calculated for each study. Our meta-analysis suggested that CCND1 G870A polymorphism was not associated with oral cancer risk (OR AA vs. GG = 1.08, 95 % CI = 0.90–1.30, P heterogeneity = 0.175; OR AA + GA vs. GG = 1.02, 95 % CI = 0.91–1.14, P heterogeneity = 0.781; OR AA vs. GA + GG = 1.16, 95 % CI = 0.98–1.36, P heterogeneity = 0.107; OR A vs. G = 1.05 95 % CI = 0.96–1.15, P heterogeneity = 0.211; OR GA vs. GG = 0.94, 95 % CI = 0.82–1.08, P heterogeneity = 0.935). However, in the subgroup analysis by ethnicity, possible significance among Asian groups was indicated in two genetic models (OR AA vs. GA + GG = 1.27, 95 % CI = 1.05–1.54, P heterogeneity = 0.572; OR allele A vs. allele G = 1.11, 95 % CI = 1.00–1.24, P heterogeneity = 0.211). Taken together, the meta-analysis revealed that CCND1 G870A polymorphism might be correlated with the susceptibility of oral cancer in Asians.
Literature
1.
Akkiz H, Bayram S, Bekar A, Akgollu E, Ozdil B. Cyclin D1 G870A polymorphism is associated with an increased risk of hepatocellular carcinoma in the Turkish population: case–control study. Cancer Epidemiol. 2010;34(3):298–302.PubMedCrossRef
2.
Balcerczak E, Pasz-Walczak G, Kumor P, Panczyk M, Kordek R, Wierzbicki R, et al. Cyclin D1 protein and CCND1 gene expression in colorectal cancer. Eur J Surg Oncol J Eur Soc Surg Oncol B Assoc Surg Oncol. 2005;31(7):721–6.
3.
Bizari L, Borim AA, Leite KR, Goncalves Fde T, Cury PM, Tajara EH, et al. Alterations of the CCND1 and HER-2/neu (ERBB2) proteins in esophageal and gastric cancers. Cancer Genet Cytogenet. 2006;165(1):41–50.PubMedCrossRef
4.
Canbay E, Eraltan IY, Cercel A, Isbir T, Gazioglu E, Aydogan F, et al. CCND1 and CDKN1B polymorphisms and risk of breast cancer. Anticancer Res. 2010;30(7):3093–8.PubMed
5.
Caplan DJ, Hertz-Picciotto I. Racial differences in survival of oral and pharyngeal cancer patients in North Carolina. J Public health Dent. 1998;58(1):36–43.PubMedCrossRef
6.
Ceschi M, Sun CL, Van Den Berg D, Koh WP, Yu MC, Probst-Hensch N. The effect of cyclin D1 (CCND1) G870A-polymorphism on breast cancer risk is modified by oxidative stress among Chinese women in Singapore. Carcinogenesis. 2005;26(8):1457–64.PubMedCrossRef
7.
Cui J, Shen L, Wang Y. Specific CCND1 G870A alleles associated with breast cancer susceptibility: a meta-analysis of 5,528 cases and 5,353 controls. Asian Pac J Cancer Prev APJCP. 2012;13(10):5023–5.CrossRef
8.
Franceschi S, Talamini R, Barra S, Baron AE, Negri E, Bidoli E, et al. Smoking and drinking in relation to cancers of the oral cavity, pharynx, larynx, and esophagus in northern Italy. Cancer Res. 1990;50(20):6502–7.PubMed
9.
Gomes CC, Drummond SN, Guimaraes AL, Andrade CI, Mesquita RA, Gomez RS. P21/WAF1 and cyclin D1 variants and oral squamous cell carcinoma. J Oral Pathol Med Off Publ Int Assoc Oral Pathol Am Acad Oral Pathol. 2008;37(3):151–6.CrossRef
10.
Holley SL, Matthias C, Jahnke V, Fryer AA, Strange RC, Hoban PR. Association of cyclin D1 polymorphism with increased susceptibility to oral squamous cell carcinoma. Oral Oncol. 2005;41(2):156–60.PubMedCrossRef
11.
Liao CT, Wang HM, Ng SH, Yen TC, Lee LY, Hsueh C, et al. Good tumor control and survivals of squamous cell carcinoma of buccal mucosa treated with radical surgery with or without neck dissection in Taiwan. Oral Oncol. 2006;42(8):800–9.PubMedCrossRef
12.
Liu W, Zhu E, Wang R, Wang L, Gao L, Yang X, et al. Cyclin D1 gene polymorphism, A870G, is associated with an increased risk of salivary gland tumors in the Chinese population. Cancer Epidemiol. 2011;35(4):e12–7.PubMedCrossRef
13.
Lu F, Gladden AB, Diehl JA. An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. Cancer Res. 2003;63(21):7056–61.PubMed
14.
Matthias C, Branigan K, Jahnke V, Leder K, Haas J, Heighway J, et al. Polymorphism within the cyclin D1 gene is associated with prognosis in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res Off J Am Assoc Cancer Res. 1998;4(10):2411–8.
15.
Moore RJ, Doherty DA, Do KA, Chamberlain RM, Khuri FR. Racial disparity in survival of patients with squamous cell carcinoma of the oral cavity and pharynx. Ethn health. 2001;6(3–4):165–77.PubMedCrossRef
16.
Nishimoto IN, Pinheiro NA, Rogatto SR, Carvalho AL, Simpson AJ, Caballero OL, et al. Cyclin D1 gene polymorphism as a risk factor for squamous cell carcinoma of the upper aerodigestive system in non-alcoholics. Oral Oncol. 2004;40(6):604–10.PubMedCrossRef
17.
Noel EE, Yeste-Velasco M, Mao X, Perry J, Kudahetti SC, Li NF, et al. The association of CCND1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers. Am J Pathol. 2010;176(6):2607–15.PubMedCrossRef
18.
Sathyan KM, Nalinakumari KR, Abraham T, Kannan S. Influence of single nucleotide polymorphisms in H-Ras and cyclin D1 genes on oral cancer susceptibility. Oral Oncol. 2006;42(6):607–13.PubMedCrossRef
19.
20.
21.
Shiboski CH, Shiboski SC, Silverman Jr S. Trends in oral cancer rates in the United States, 1973–1996. Community Dent Oral Epidemiol. 2000;28(4):249–56.PubMedCrossRef
22.
Solomon DA, Wang Y, Fox SR, Lambeck TC, Giesting S, Lan Z, et al. Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation. J Biol Chem. 2003;278(32):30339–47.PubMedCrossRef
23.
Sutherland RL, Musgrove EA. Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models. Breast Cancer Res BCR. 2002;4(1):14–7.CrossRef
24.
Swango PA. Cancers of the oral cavity and pharynx in the United States: an epidemiologic overview. J Public health Dent. 1996;56(6):309–18.PubMedCrossRef
25.
Tsai MH, Tsai CW, Tsou YA, Hua CH, Hsu CF, Bau DT. Significant association of cyclin D1 single nucleotide polymorphisms with oral cancer in Taiwan. Anticancer Res. 2011;31(1):227–31.PubMed
26.
Wang L, Habuchi T, Mitsumori K, Li Z, Kamoto T, Kinoshita H, et al. Increased risk of prostate cancer associated with AA genotype of cyclin D1 gene A870G polymorphism. Int J Cancer J Int Cancer. 2003;103(1):116–20.CrossRef
27.
Wang L, Habuchi T, Takahashi T, Mitsumori K, Kamoto T, Kakehi Y, et al. Cyclin D1 gene polymorphism is associated with an increased risk of urinary bladder cancer. Carcinogenesis. 2002;23(2):257–64.PubMedCrossRef
28.
Wang W, Zhao Y, Yang J, Lin B, Gu H, Cao X, et al. Cyclin D1 polymorphism and oral cancer: a meta-analysis. Mol Biol Rep. 2013;40(1):87–95.PubMedCrossRef
29.
Wong YK, Lin SC, Chang CS, Tseng YH, Liu CJ, Lin HC, et al. Cyclin D1 genotype in areca-associated oral squamous cell carcinoma. J Oral Pathol Med Off Publ Int Assoc Oral Pathol Am Acad Oral Pathol. 2003;32(5):265–70.CrossRef
30.
Zhuo XL, Ling JJ, Zhao HY, Zhou Y, Song YF, Tan YH. Lack of association of the cyclin D1 G870A variation with oral carcinoma risk: Evidence from 2,404 subjects. Exp Ther Med. 2012;4(4):748–54.PubMedCentralPubMed
Metadata
Title
Association between Cyclin D1 polymorphism and oral cancer susceptibility: a meta-analysis
Authors
Lili Wang
Zhiying Wang
Xiuqiu Gao
Xin Li
Xirao Sun
Changfu Liu
Publication date
01-02-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 2/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1154-8

Other articles of this Issue 2/2014

Tumor Biology 2/2014 Go to the issue

Research Article

Prognostic value of EpCAM/MUC1 mRNA-positive cells in non-small cell lung cancer patients

Research Article

G84E mutation in HOXB13 is firmly associated with prostate cancer risk: a meta-analysis

Research Article

Polymorphisms in the vitamin D receptor gene and the lung cancer risk

Research Article

COL1A1 polymorphism is associated with risks of osteosarcoma susceptibility and death

Research Article

Oxymatrine induces mitochondria dependent apoptosis in human osteosarcoma MNNG/HOS cells through inhibition of PI3K/Akt pathway

Research Article

Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits